Idexx Laboratories (IDXX) Stock Forecast & Price Target

Compare

2,078 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IDXX Analyst Ratings

Moderate Buy

6 Buy

3 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Idexx

Laboratories

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IDXX Stock 12 Month Forecast

Average Price Target

$724.38

▲(17.18% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Idexx Laboratories in the last 3 months. The average price target is $724.38 with a high forecast of $785.00 and a low forecast of $640.00. The average price target represents a 17.18% change from the last price of $618.17.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"412":"$412","599":"$599","786":"$786","505.5":"$505.5","692.5":"$692.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":785,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$785.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":724.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$724.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":640,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$640.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[412,505.5,599,692.5,786],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,535.54,554.7292307692308,573.9184615384615,593.1076923076923,612.296923076923,631.4861538461538,650.6753846153846,669.8646153846154,689.0538461538462,708.2430769230768,727.4323076923076,746.6215384615384,765.8107692307692,{"y":785,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,535.54,550.0661538461538,564.5923076923077,579.1184615384615,593.6446153846153,608.1707692307692,622.6969230769231,637.2230769230769,651.7492307692307,666.2753846153846,680.8015384615385,695.3276923076924,709.8538461538461,{"y":724.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,535.54,543.5753846153846,551.6107692307692,559.6461538461538,567.6815384615385,575.7169230769231,583.7523076923077,591.7876923076923,599.8230769230769,607.8584615384615,615.8938461538462,623.9292307692308,631.9646153846154,{"y":640,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":476.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":477.84,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":495.42,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":417.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":430.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":413.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":422.05,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":437.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":418.57,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":471.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":514.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":542.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":535.54,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$785.00

Average Price Target$724.38

Lowest Price Target$640.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Keith Devas

Jefferies

$785

Buy

26.99%

Upside

Reiterated

08/18/25

Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Medtronic (NYSE: MDT) and Idexx Laboratories (NASDAQ: IDXX)

Erin Wright

Morgan Stanley

$722→$765

Buy

23.75%

Upside

Reiterated

08/15/25

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (NASDAQ: IDXX) and Aardvark Therapeutics, Inc. (NASDAQ: AARD)Table data – Overweight; PT increased from 722.00 to 765.00.

Daniel Clark

Leerink Partners

$745

Buy

20.52%

Upside

Reiterated

08/15/25

Leerink Partners Sticks to Their Buy Rating for Idexx Laboratories (IDXX)

Mark Massaro

BTIG

$785

Buy

26.99%

Upside

Reiterated

08/15/25

Idexx Laboratories (IDXX) Gets a Buy from BTIG

Ryan Daniels

William Blair

―

Buy

―

Reiterated

08/14/25

Idexx Laboratories: A Strong Buy Amidst Veterinary Healthcare Market ResilienceWe continue to view the veterinary healthcare market as a relative safe haven investment area for investors, and we believe the industry is fairly recession resilient (i.e., largely inelastic demand, solid pricing power, and favorable demographic trends) and lacks many of the investment risks present in the human healthcare space. Given the above, we have conviction in the company’s management team, long- term organic growth trajectory, and business franchise overall; thus, we view Idexx as a core long-term holding and reiterate our Outperform rating on the stock.

David Westenberg

Piper Sandler

$510→$700

Hold

13.24%

Upside

Reiterated

08/11/25

Piper Sandler Reaffirms Their Hold Rating on Idexx Laboratories (IDXX)

Cira Diagnissa

TR | OpenAI - 4o

$775

Buy

25.37%

Upside

Reiterated

08/11/25

AI Generated ArticleAI Generated Article

Jonathan Block

Stifel Nicolaus

$540→$640

Hold

3.53%

Upside

Reiterated

08/04/25

Idexx Laboratories price target raised to $640 from $540 at StifelIdexx Laboratories price target raised to $640 from $540 at Stifel

Chris Schott

J.P. Morgan

$550→$675

Buy

9.19%

Upside

Reiterated

08/04/25

Idexx Laboratories price target raised to $675 from $550 at JPMorganIdexx Laboratories price target raised to $675 from $550 at JPMorgan

Michael Ryskin

Bank of America Securities

$550→$700

Hold

13.24%

Upside

Reiterated

08/04/25

Idexx Laboratories Hold Rating: Balancing Market Softness with Potential Product Growth

Balaji Prasad

Barclays

$520

Buy

-15.88%

Downside

Reiterated

02/04/25

Barclays Sticks to Its Buy Rating for Idexx Laboratories (IDXX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Keith Devas

Jefferies

$785

Buy

26.99%

Upside

Reiterated

08/18/25

Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Medtronic (NYSE: MDT) and Idexx Laboratories (NASDAQ: IDXX)

Erin Wright

Morgan Stanley

$722→$765

Buy

23.75%

Upside

Reiterated

08/15/25

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (NASDAQ: IDXX) and Aardvark Therapeutics, Inc. (NASDAQ: AARD)Table data – Overweight; PT increased from 722.00 to 765.00.

Daniel Clark

Leerink Partners

$745

Buy

20.52%

Upside

Reiterated

08/15/25

Leerink Partners Sticks to Their Buy Rating for Idexx Laboratories (IDXX)

Mark Massaro

BTIG

$785

Buy

26.99%

Upside

Reiterated

08/15/25

Idexx Laboratories (IDXX) Gets a Buy from BTIG

Ryan Daniels

William Blair

―

Buy

―

Reiterated

08/14/25

David Westenberg

Piper Sandler

$510→$700

Hold

13.24%

Upside

Reiterated

08/11/25

Piper Sandler Reaffirms Their Hold Rating on Idexx Laboratories (IDXX)

Cira Diagnissa

TR | OpenAI - 4o

$775

Buy

25.37%

Upside

Reiterated

08/11/25

AI Generated ArticleAI Generated Article

Jonathan Block

Stifel Nicolaus

$540→$640

Hold

3.53%

Upside

Reiterated

08/04/25

Idexx Laboratories price target raised to $640 from $540 at StifelIdexx Laboratories price target raised to $640 from $540 at Stifel

Chris Schott

J.P. Morgan

$550→$675

Buy

9.19%

Upside

Reiterated

08/04/25

Idexx Laboratories price target raised to $675 from $550 at JPMorganIdexx Laboratories price target raised to $675 from $550 at JPMorgan

Michael Ryskin

Bank of America Securities

$550→$700

Hold

13.24%

Upside

Reiterated

08/04/25

Idexx Laboratories Hold Rating: Balancing Market Softness with Potential Product Growth

Balaji Prasad

Barclays

$520

Buy

-15.88%

Downside

Reiterated

02/04/25

Barclays Sticks to Its Buy Rating for Idexx Laboratories (IDXX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Idexx Laboratories

1 Month

xxx

Success Rate

8/16 ratings generated profit

Average Return

-0.11%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -0.11% per trade.

3 Months

xxx

Success Rate

15/26 ratings generated profit

Average Return

+2.32%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.69% of your transactions generating a profit, with an average return of +2.32% per trade.

1 Year

Erin WrightMorgan Stanley

Success Rate

20/26 ratings generated profit

Average Return

+25.45%

reiterated a buy rating last month

Copying Erin Wright's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +25.45% per trade.

2 Years

xxx

Success Rate

22/26 ratings generated profit

Average Return

+37.57%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 84.62% of your transactions generating a profit, with an average return of +37.57% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IDXX Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IDXX has received 22 Buy Ratings, 5 Hold Ratings, and 1 Sell Ratings. IDXX average Analyst price target in the past 3 months is 724.38.

Each month's total comprises the sum of three months' worth of ratings.

IDXX Financial Forecast

IDXX Earnings Forecast

Next quarter’s earnings estimate for IDXX is $3.13 with a range of $2.99 to $3.18. The previous quarter’s EPS was $3.63. IDXX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.42% of the time in the same period. In the last calendar year IDXX has Outperformed its overall industry.

IDXX Sales Forecast

Next quarter’s sales forecast for IDXX is $1.07B with a range of $1.06B to $1.08B. The previous quarter’s sales results were $1.11B. IDXX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 33.82% of the time in the same period. In the last calendar year IDXX has Outperformed its overall industry.

IDXX Stock Forecast FAQ

What is IDXX’s average 12-month price target, according to analysts?

Based on analyst ratings, Idexx Laboratories’s 12-month average price target is 724.38.

What is IDXX’s upside potential, based on the analysts’ average price target?

Idexx Laboratories has 17.18% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IDXX a Buy, Sell or Hold?

Idexx Laboratories has a consensus rating of Moderate Buy which is based on 6 buy ratings, 3 hold ratings and 0 sell ratings.

What is Idexx Laboratories’s price target?

The average price target for Idexx Laboratories is 724.38. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $785.00 ,the lowest forecast is $640.00. The average price target represents 17.18% Increase from the current price of $618.17.

What do analysts say about Idexx Laboratories?

Idexx Laboratories’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of IDXX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Idexx Laboratories (IDXX) Stock Forecast & Price Target

IDXX Analyst Ratings

IDXX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Idexx Laboratories

IDXX Analyst Recommendation Trends

IDXX Financial Forecast

IDXX Earnings Forecast

IDXX Sales Forecast

IDXX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts